Lipum
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Lipum Announces Peer-Reviewed Publication of Positive First-in-Human Phase I Results for SOL-116
Lipum today announced that results from the First-in-Human (FIH) Phase I trial of its drug candidate SOL-116 have been published in the peer-reviewed journal RMD Open. SOL-116 is a first-in-class humanised monoclonal antibody targeting bile salt-stimulated lipase (BSSL), a novel mechanism for rheumatoid arthritis (RA) and other chronic inflammatory diseases.
The randomised, double-blind, placebo-controlled trial (NCT05576012) evaluated subcutaneous SOL-116 in 56 participants - 48 healthy volunteers and 8 patients with mild RA. SOL-116 was safe and well tolerated across all dose levels, with mainly mild adverse events and a low immunogenicity profile. Exposure increased dose-proportionally with a long half-life supporting infrequent dosing, and free circulating BSSL was effectively and durably reduced, confirming target engagement.
"These are strong first-in-human results: a favourable safety and pharmacokinetic profile and clear confirmation that SOL-116 reaches its target. This is the foundation we wanted before testing efficacy in patients. We now look forward to our fully funded Phase IIa proof-of-concept study, now in start-up," says Peter Hovstadius, MD, PhD, Chief Medical Officer at Lipum.
Read more on Lipum’s website, where access to the publication is available.
| Datum | 2026-07-06, kl 14:20 |
| Källa | MFN |